Search clinical trials for: Oral [14C]PF-07081532

Total 234 results

Pfizer

Completed

A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

Healthy Participants

Netherlands
Pfizer

Terminated

A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction

Renal Impairment | Type 2 Diabetes

United States
Pfizer

Completed

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Pfizer

Not yet recruiting

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

Healthy Participants
Pfizer

Completed

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

Healthy Participants

United States
Pfizer

Completed

A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

Healthy Participants

Netherlands
Pfizer

Completed

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

Obesity | Overweight

United States
Pfizer

Completed

Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants

Healthy

Belgium
Pfizer

Completed

A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction

Healthy Volunteers | Hepatic Impairment

United States
Pfizer

Completed

Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects

Healthy Male Subjects

Netherlands
Pfizer

Terminated

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

Obesity | Diabetes Mellitus

United States, Hungary, Canada, Japan, Poland, Puerto Rico, Bulgaria, Czechia
Pfizer

Completed

Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600. (B7981011)

Healthy Volunteers

Netherlands
Pfizer

Completed

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

Healthy Volunteer

Netherlands
Pfizer

Completed

A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers

Healthy

United States
Pfizer

Completed

A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body

Healthy

United States
Pfizer

Completed

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

Healthy

United States
Pfizer

Completed

A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants

Healthy

Netherlands
Pfizer

Completed

Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers

Healthy Volunteers

United States
AstraZeneca
Quotient Sciences

Completed

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Cardiovascular Disease

United Kingdom
Pfizer

Terminated

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

Obesity

United States
Pfizer

Completed

Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer

Neuroinflammation

United States
Pfizer

Completed

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

HCV

United States
Takeda

Completed

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

Healthy Volunteers

United States
Theravance Biopharma

Completed

TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

Bowel Diseases, Inflammatory | Intestinal Disorders

United States
Pfizer

Withdrawn

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.

Healthy Participants
Neurocrine Biosciences
Takeda

Completed

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

Healthy Volunteers

United States
Yale University
National Institute on Drug Abuse (NIDA); Medical University of South Carolina; Johns Hopkins University and other collaborators

Completed

Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) (FAAH-I MULTI)

Cannabis Use Disorder

United States
Pfizer

Completed

Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects

Healthy

Belgium
University of Oxford

Completed

PF-04995274 and Emotional Processing in Treatment Resistant Depression (RESTART)

Treatment Resistant Depression | Depression, Unipolar

United Kingdom
Pfizer

Completed

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
AstraZeneca
Quotient Sciences

Completed

A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831

Cardiovascular Disease

United Kingdom
Boehringer Ingelheim

Completed

Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects

Healthy
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Healthy Volunteers

United States
Pfizer

Completed

A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning

Healthy

United States
Prana Biotechnology Limited

Completed

Absorption, Metabolism and Excretion Study of [14C]PBT2 and Absolute Bioavailability of PBT2

Healthy Volunteers

United Kingdom
Biogen

Completed

Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation

Healthy

United States
Takeda

Completed

Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants

Healthy Volunteers

United States
Medela AG

Completed

Impact of Breast Shield Designs on Dynamics of Breast Pumping (BSD)

Lactation

Switzerland
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

Parkinson Disease

United States, France, Israel, Germany
AstraZeneca
Quotient Sciences

Completed

An ADME Study of [14C]AZD0780 in Healthy Male Subjects

Cardiovascular Diseases

United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States
Aquinox Pharmaceuticals (Canada) Inc.
Quotient Clinical

Completed

Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125 (ADME)

Healthy Volunteer

United Kingdom
Basilea Pharmaceutica

Completed

A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males

Fungal Infection

United Kingdom
ViiV Healthcare

Completed

Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254

HIV Infections

United Kingdom
Galapagos NV

Completed

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970

Healthy

United Kingdom
Corcept Therapeutics

Completed

Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants

Healthy

United Kingdom
Boehringer Ingelheim

Completed

Investigation of the Metabolism and Pharmacokinetics of Ambroxol in Healthy Male Volunteers

Healthy
Pfizer

Completed

Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus Type 2

United States
Pfizer

Completed

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

Plaque Psoriasis

United States
Galapagos NV

Completed

A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an Injection

Healthy

United Kingdom

3

Subscribe